Synthesis of Biologically Active Piperidine Metabolites of Clopidogrel: Determination of Structure and Analyte Development
作者:Scott A. Shaw、Balu Balasubramanian、Samuel Bonacorsi、Janet Caceres Cortes、Kevin Cao、Bang-Chi Chen、Jun Dai、Carl Decicco、Animesh Goswami、Zhiwei Guo、Ronald Hanson、W. Griffith Humphreys、Patrick Y. S. Lam、Wenying Li、Arvind Mathur、Brad D. Maxwell、Quentin Michaudel、Li Peng、Andrew Pudzianowski、Feng Qiu、Shun Su、Dawn Sun、Adrienne A. Tymiak、Benjamin P. Vokits、Bei Wang、Ruth Wexler、Dauh-Rurng Wu、Yingru Zhang、Rulin Zhao、Phil S. Baran
DOI:10.1021/acs.joc.5b00632
日期:2015.7.17
Clopidogrel is a prodrug anticoagulant with activemetabolites that irreversibly inhibit the platelet surface GPCR P2Y12 and thus inhibit platelet activation. However, gaining an understanding of patient response has been limited due to imprecise understanding of metabolite activity and stereochemistry, and a lack of acceptable analytes for quantifying in vivo metabolite formation. Methods for the
New compounds, namely, (7aS,2′S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.
[EN] STABLE COMPOSITIONS OF (7AS,2'S)-2-OXOCLOPIDOGREL AND ITS PHARMACEUTICAL SALTS<br/>[FR] COMPOSITIONS STABLES DE (7AS, 2'S)-2-OXOCLOPIDOGREL ET SES SELS PHARMACEUTIQUES
申请人:IPCA LABORATORIES LTD
公开号:WO2021070200A2
公开(公告)日:2021-04-15
The present invention discloses stable oral pharmaceutical composition containing therapeutically effective amount of (7aS,2'S)-2-oxoclopidogrel and/or its salts or derivatives, in combination with pharmaceutically acceptable adjuvants or carriers. More particularly, the present invention discloses highly pure (7aS,2'S)-2-oxoclopidogrel and/or its salts, processes for manufacturing pure and stable (7aS,2'S)-2-oxoclopidogrel and stable compositions having a shelf-life of at least one year or more.